Genelux Corp Files 8-K: Regulation FD & Exhibits
Ticker: GNLX · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1231457
| Field | Detail |
|---|---|
| Company | Genelux Corp (GNLX) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
GENELUX filed an 8-K for Reg FD and exhibits. No major news yet.
AI Summary
On April 9, 2024, Genelux Corporation filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, suggesting it may be a routine filing or an update on previously disclosed information.
Why It Matters
This filing indicates Genelux Corporation is providing updates or disclosures required by the SEC, which could contain important information for investors regarding compliance and financial reporting.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification without specific material events or financial data that would indicate immediate risk.
Key Players & Entities
- Genelux Corporation (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Westlake Village, California (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Genelux Corporation?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is Genelux Corporation's principal executive office address?
Genelux Corporation's principal executive office is located at 2625 Townsgate Road, Suite 230, Westlake Village, California 91361.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 9, 2024.
What is Genelux Corporation's SIC code?
Genelux Corporation's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the Commission File Number for Genelux Corporation?
The Commission File Number for Genelux Corporation is 001-41599.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-04-09 16:15:48
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex99-1.htm (EX-99.1) — 33KB
- ex99-1_001.jpg (GRAPHIC) — 302KB
- ex99-1_002.jpg (GRAPHIC) — 608KB
- ex99-1_003.jpg (GRAPHIC) — 244KB
- ex99-1_004.jpg (GRAPHIC) — 320KB
- ex99-1_005.jpg (GRAPHIC) — 336KB
- ex99-1_006.jpg (GRAPHIC) — 280KB
- ex99-1_007.jpg (GRAPHIC) — 265KB
- ex99-1_008.jpg (GRAPHIC) — 289KB
- ex99-1_009.jpg (GRAPHIC) — 97KB
- ex99-1_010.jpg (GRAPHIC) — 248KB
- ex99-1_011.jpg (GRAPHIC) — 303KB
- ex99-1_012.jpg (GRAPHIC) — 298KB
- ex99-1_013.jpg (GRAPHIC) — 356KB
- ex99-1_014.jpg (GRAPHIC) — 362KB
- ex99-1_015.jpg (GRAPHIC) — 351KB
- ex99-1_016.jpg (GRAPHIC) — 229KB
- ex99-1_017.jpg (GRAPHIC) — 321KB
- ex99-1_018.jpg (GRAPHIC) — 325KB
- ex99-1_019.jpg (GRAPHIC) — 284KB
- ex99-1_020.jpg (GRAPHIC) — 98KB
- ex99-1_021.jpg (GRAPHIC) — 219KB
- ex99-1_022.jpg (GRAPHIC) — 337KB
- ex99-1_023.jpg (GRAPHIC) — 306KB
- ex99-1_024.jpg (GRAPHIC) — 250KB
- ex99-1_025.jpg (GRAPHIC) — 255KB
- ex99-1_026.jpg (GRAPHIC) — 271KB
- ex99-1_027.jpg (GRAPHIC) — 297KB
- ex99-1_028.jpg (GRAPHIC) — 270KB
- ex99-1_029.jpg (GRAPHIC) — 185KB
- ex99-1_030.jpg (GRAPHIC) — 318KB
- ex99-1_031.jpg (GRAPHIC) — 297KB
- ex99-1_032.jpg (GRAPHIC) — 267KB
- ex99-1_033.jpg (GRAPHIC) — 303KB
- ex99-1_034.jpg (GRAPHIC) — 314KB
- ex99-1_035.jpg (GRAPHIC) — 323KB
- ex99-1_036.jpg (GRAPHIC) — 248KB
- ex99-1_037.jpg (GRAPHIC) — 346KB
- ex99-1_038.jpg (GRAPHIC) — 440KB
- ex99-1_039.jpg (GRAPHIC) — 338KB
- ex99-1_040.jpg (GRAPHIC) — 329KB
- 0001493152-24-014071.txt ( ) — 16535KB
- gnlx-20240409.xsd (EX-101.SCH) — 3KB
- gnlx-20240409_lab.xml (EX-101.LAB) — 33KB
- gnlx-20240409_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelux Corporation Date: April 9, 2024 By: /s/ Thomas Zindrick, J.D. Thomas Zindrick, J.D. President and Chief Executive Officer